<DOC>
	<DOCNO>NCT00777478</DOCNO>
	<brief_summary>The primary objective Phase 1 study identify recommend dose capiri sunitinib combination therapy subsequent phase II trial .</brief_summary>
	<brief_title>Capiri-sutent Phase-1 Advanced Colo-rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histological proof colorectal cancer Patients fail one previous line systemic treatment advance disease ( one treatment line ) , either fluoropyrimidine monotherapy combination oxaliplatin and/or bevacizumab . No prior treatment irinotecan sunitinib Age ≥ 18 year WHO PS 01 ( see Appendix 3 , correspond Karnofsky ≥ 70 % ) Life expectancy ≥ 12 week Written inform consent No measurable disease accord RECIST criterion . Prior anticancer therapy &lt; 3 week first dose . For cetuximab &lt; 30 day bevacizumab &lt; 60 day prior first dose . Unresolved toxicity &gt; CTC gr 1 previous anticancer therapy ( include radiotherapy ) except alopecia . Inadequate bone marrow function ( Hb ≤ 5.6 mmol/L , absolute neutrophil count ( ANC ) ≤ 1.5 x 109/L , platelet ≤100 x 109/L ) renal dysfunction ( serum creatinine ≥ 1.5x ULN glomerular filtration rate ≤ 50 ml/min ) Prothrombin time ( PT ) activate partial thromboplastin time ( APTT ) &gt; 2x ULRR Hepatic dysfunction ( serum bilirubin ≥ 1.5x ULN , serum transaminase ≥ 2.5 x ULN ) Greater +1 proteinuria two consecutive dipstick take less 2 week apart unless urinary protein &lt; 1,5 g 24 Hr period . Pregnant lactating woman History clinical signs/symptoms CNS metastases Previous intolerance fluoropyrimidine therapy , know dihydropyrimidine dehydrogenase ( DPD ) deficiency . Known hypersensitivity irinotecan sunitinib excipients . No major surgery &lt; 4 week prior study entry . No radiotherapy &lt; 4 week prior study entry except palliative radiotherapy focal site . Any evidence concurrent severe uncontrolled disease ( i.e . uncontrolled hypertension , congestive heart failure , myocardial infarction &lt; 6 month , chronic active infection , poorly regulate diabetes mellitus ) Any previous significant cardiovascular event previous fluoropyrimidine therapy ( i.e . myocardial ischemia infarction , arterial thrombosis , pulmonary embolus ) Mean Qtc Bazetts correction &gt; 470 msec screen ECG , history familial long QT syndrome Significant haemorrhage ( &gt; 30 ml bleeding/episode last 3 month ) haemoptysis ( &gt; 5 ml fresh blood previous 4 week ) History impairment gastrointestinal function disease may significantly impair absorption oral drug ( i.e . uncontrolled nausea , vomit , diarrhoea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Concomitant use medication may significantly affect hepatic cytochrome P450 drug metabolize activity way enzyme induction inhibition &lt; 2 week first dose throughout study period ( see Appendix 2 ) Other concomitant anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Sunitinib</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>